ascopubs.org

Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: Safety analysis from the phase II NIBIT-MESO-1 study.

Biomarkers of pembrolizumab (P) activity in mesothelioma (MM): Results from a phase II trial. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a ...
The Globe and Mail

NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In a recent update, NovoCure Ltd.
ascopubs.org

Tremelimumab and durvalumab (MEDI4736) combination for first and second-line treatment of mesothelioma patients: The NIBIT-MESO-1 study.

Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients ...